Menu Search
Equities

Flerie AB

FLERIE:STO

Flerie AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)45.10
  • Today's Change0.51 / 1.14%
  • Shares traded5.59k
  • 1 Year change+96.94%
  • Beta-0.0028
Data delayed at least 15 minutes, as of Nov 22 2024 10:55 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy1
Outperform0
Hold1
Sell0
Strong Sell0

Share price forecast

The 3 analysts offering 12 month price targets for Flerie AB have a median target of 44.00, with a high estimate of 68.00 and a low estimate of 27.00. The median estimate represents a -1.32% decrease from the last price of 44.59.
High52.5%68.00
Med-1.3%44.00
Low-39.4%27.00

Earnings history & estimates in SEK

Flerie AB reported annual 2022 losses of -19.00 per share on Feb 23, 2023.
Average growth rate-2,270.32%
More ▼

Revenue history & estimates in SEK

InDex Pharmaceuticals Holding AB (publ) did not report revenues for the full year 2023. However, during the prior year the company reported revenues of 0.00.
Average growth rate-40.06%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.